GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Common Stock

Chimeric Therapeutics (ASX:CHM) Common Stock : A$59.89 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Common Stock?

Chimeric Therapeutics's quarterly common stock increased from Dec. 2022 (A$52.97 Mil) to Jun. 2023 (A$53.93 Mil) and increased from Jun. 2023 (A$53.93 Mil) to Dec. 2023 (A$59.89 Mil).

Chimeric Therapeutics's annual common stock increased from Jun. 2021 (A$37.37 Mil) to Jun. 2022 (A$51.81 Mil) and increased from Jun. 2022 (A$51.81 Mil) to Jun. 2023 (A$53.93 Mil).


Chimeric Therapeutics Common Stock Historical Data

The historical data trend for Chimeric Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Common Stock Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Common Stock
37.37 51.81 53.93

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Common Stock Get a 7-Day Free Trial 38.71 51.81 52.97 53.93 59.89

Chimeric Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Chimeric Therapeutics (ASX:CHM) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines